Hepion Pharmaceuticals Inc (HEPA) — Cash Flow-to-Debt Ratio
Hepion Pharmaceuticals Inc (HEPA) has a Cash Flow-to-Debt Ratio of -0.83x as of December 2025, meaning its operating cash flow of $-332.77K could theoretically repay -1% of its total liabilities ($402.40K) in one year. See HEPA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hepion Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Hepion Pharmaceuticals Inc across 14 annual periods. For the full cash flow conversion analysis, see HEPA cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Hepion Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Hepion Pharmaceuticals Inc. Check how high is Hepion Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -8.13x | $-3.27 Million | $402.40K | ▼ -55.2% |
| 2024 | -5.24x | $-18.22 Million | $3.48 Million | ▼ -38.6% |
| 2023 | -3.78x | $-40.89 Million | $10.81 Million | ▼ -12.4% |
| 2022 | -3.37x | $-34.96 Million | $10.39 Million | ▼ -13.8% |
| 2021 | -2.96x | $-31.22 Million | $10.56 Million | ▼ -48.7% |
| 2020 | -1.99x | $-16.17 Million | $8.12 Million | ▼ -31.4% |
| 2019 | -1.51x | $-7.57 Million | $4.99 Million | ▲ +39.8% |
| 2018 | -2.52x | $-15.65 Million | $6.21 Million | ▼ -131.6% |
| 2017 | -1.09x | $-8.21 Million | $7.55 Million | ▲ +22.6% |
| 2016 | -1.40x | $-16.56 Million | $11.79 Million | ▲ +71.9% |
| 2015 | -4.99x | $-9.67 Million | $1.94 Million | ▼ -1706.5% |
| 2014 | -0.28x | $-1.36 Million | $4.93 Million | ▲ +0.0% |
| 2013 | -0.28x | $-1.36 Million | $4.93 Million | ▼ -78656.3% |
| 2012 | 0.00x | $-79.70 | $227.21K | — |